(Q54301896)

27 May 2018

title

Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes. (English)

1 reference

27 May 2018

0 references

Philippe Aegerter

3

0 references

author name string

Stéphanie Moreau

1

1 reference

27 May 2018

Philippe Saiag

2

1 reference

27 May 2018

Daphné Bosset

4

1 reference

27 May 2018

Christine Longvert

5

1 reference

27 May 2018

Zofia Hélias-Rodzewicz

6

1 reference

27 May 2018

Cristi Marin

7

1 reference

27 May 2018

Frédérique Peschaud

8

1 reference

27 May 2018

Sophie Chagnon

9

1 reference

27 May 2018

Utte Zimmermann

10

1 reference

27 May 2018

Thierry Clerici

11

1 reference

27 May 2018

Jean-François Emile

12

1 reference

27 May 2018

publication date

7 July 2012

1 reference

27 May 2018

Annals of Surgical Oncology

published in

1 reference

27 May 2018

volume

19

1 reference

27 May 2018

issue

13

1 reference

27 May 2018

page(s)

4314-4321

1 reference

27 May 2018

Final version of 2009 AJCC melanoma staging and classification

cites work

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Examination of mutations in BRAF, NRAS, and PTEN in primary cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Somatic alterations in the melanoma genome: a high-resolution array-based comparative genomic hybridization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Analysis of BRAF mutation in primary and metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Variants of the MATP/SLC45A2 gene are protective for melanoma in the French population

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Reporting recommendations for tumor marker prognostic studies (REMARK).

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Mutations of the BRAF gene in benign and malignant melanocytic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Stability of BRAF V600E mutation in metastatic melanoma: new insights for therapeutic success?

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Determinants of BRAF mutations in primary melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1245%2FS10434-012-2457-5

10.1245/S10434-012-2457-5

21 January 2018

Identifiers

DOI

1 reference

27 May 2018

Dimensions Publication ID

1007858751

0 references

1 reference

27 May 2018